---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-040752"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:13:04.611035+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Israeli Ministry of Health approves Elite's generic Adderall; first shipment months away

## Summary
- Israeli Ministry of Health approved Elite's generic Adderall (mixed amphetamine salts) in 10mg, 20mg, 30mg tablets on Oct 7, 2024.
- Elite will supply to exclusive distributor Dexcel Pharma for the Israeli market; Dexcel handles sales/marketing at its expense.
- Product jointly owned by Elite and Mikah Pharma; first shipment depends on licensee orders, DEA quotas, and manufacturing.
- Under license agreement, Dexcel pays transfer price and shares profits under certain conditions.

## SEC filing metadata
- accession: 0001493152-24-040752
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315224040752/0001493152-24-040752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315224040752/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-040752
- JSON: https://secwatch.observer/filing/0001493152-24-040752.json
- Plain text: https://secwatch.observer/filing/0001493152-24-040752.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.